文献速递炎症性肠病

炎症性肠病患者由静脉转为皮下维得利珠单抗治疗的真实世界数据

Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-04-25

本研究前瞻性随访89例炎症性肠病患者(48例克罗恩病、41例溃疡性结肠炎),由静脉转为皮下维得利珠单抗维持治疗6个月,部分亚组随访12个月。主要终点粪便钙卫蛋白在克罗恩病中显著下降,在溃疡性结肠炎中未显著变化;临床指标、缓解率、血浆CRP及生活质量保持不变,满意度高,年治疗费用降低15%。

要点

  • 89例患者由静脉转为皮下维得利珠单抗,6个月和12个月药物持续率分别为95.5%和88.5%。
  • 粪便钙卫蛋白在克罗恩病中显著下降,在溃疡性结肠炎中未显著下降。
  • 皮下治疗中位谷浓度为静脉治疗的2.3倍,年治疗费用降低15%。

核心结论

  • 由静脉转为皮下维得利珠单抗可保持治疗有效性、安全性、高患者满意度和低停药率,且费用降低。

研究设计与样本

  • 前瞻性研究,89例炎症性肠病患者(48例克罗恩病、41例溃疡性结肠炎)由静脉转为皮下维得利珠单抗维持治疗,随访6个月,亚组随访12个月。

主要发现

  • 粪便钙卫蛋白在克罗恩病中显著下降,在溃疡性结肠炎中未显著下降。
  • 临床指数、缓解率、血浆CRP水平及生活质量评分保持不变。
  • 6个月和12个月药物持续率分别为95.5%和88.5%。
  • 转换前后不良事件频率相似,未发生严重不良事件,1.2%患者出现一过性严重局部注射反应。
  • 皮下治疗中位谷浓度为静脉治疗的2.3倍,年治疗费用降低15%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Vedolizumab is a gut-selective treatment approved for Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of vedolizumab was approved. The aims of this study were to evaluate efficacy, safety, pharmacokinetics, patient experience and costs following a switch from intravenous to subcutaneous vedolizumab treatment. METHODS: Patients were switched from intravenous to subcutaneous vedolizumab maintenance treatment and followed prospectively for 6 months and a subgroup for 12 months. The primary endpoint was change in faecal calprotectin levels. Furthermore, we evaluated clinical disease activity, remission rates, plasma CRP, drug persistence, adverse events, local injection reactions, serum drug concentrations, patient satisfaction, quality-of-life and treatment costs. RESULTS: Eighty-nine patients were included (48 CD; 41 UC). Faecal calprotectin decreased significantly in CD but not in UC. Clinical indices, remission rates, plasma CRP levels and quality-of-life scores remained unchanged. Patients that had been on standard compared to optimised IV vedolizumab dosing displayed similar outcomes on standard SC dosing. Drug persistence at 6 and 12 months was 95.5% and 88.5%, respectively. Frequencies of adverse events were similar before and after the switch. No serious adverse events occurred. Transient severe local injection reactions were experienced by 1.2% of patients. Median vedolizumab trough levels were 2.3 times higher on subcutaneous compared to intravenous treatment. Patient satisfaction was generally high. Annualised treatment costs were reduced by 15% following the switch. CONCLUSIONS: The switch from intravenous to subcutaneous vedolizumab could be done with preserved therapeutic effectiveness, safety, high patient satisfaction and low discontinuation rate, at a reduced cost.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bergqvist V, Holmgren J, Klintman D, et al. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35470449. doi:10.1111/apt.16927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。